跳至主要内容
临床试验/TCTR20180812003
TCTR20180812003尚未招募未知

Rate of severe cutaneous adverse reactions due to first line Anti-tuberculosis drugs, Health Product Vigilance Center database; Food and Drug Administration, Ministry of Public Health

Tipsiri Chaikong0 个研究点目标入组 3,500 人开始时间: 2018年8月12日最近更新:
适应症

试验速览

阶段
未知
状态
尚未招募
发起方
入组人数
3,500

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
0 N/A (No limit) 至 0 N/A (No limit)(—)
性别
All

入选标准

  • 1. reports that the culprit drugs was Isoniazid, Rifampin, Pyrazinamide, Ethambutol, Streptomycin
  • 2. reports that adverse reactions was Stevens-Johnson syndrome (SJS), Toxic Epidermal Necrolysis (TEN), Drug reaction with eosinophilia and Systemic symptoms/ Drug-induced hypersensitivity syndrome (DRESS/ DIHS), Acute Generalized Exanthematous Pustulosis (AGEP) or the rash that was reported to be serious rash

排除标准

  • The report that these data incompleted; report date, gender, age, drug allergy history, culprit drug name, start date, stop date, ADRs occurrence date, ADRs, causality relationship, seriousness of reactions, patient result from SCARs

研究者

发起方
Tipsiri Chaikong

相似试验